Inflammatory status in sepsis alters efficacy of interleukin-18 binding protein therapy

Critical Care Medicine

Volumn 31, Issue 8, 2003, Pages 2096-2101

  Remick, Daniel G ^a,b   Bolgos, Gerald E ^a   Siddiqui, Javed ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Med Sci I   (United States)

Author keywords

Cytokines; Interleukin 6; Lymphocytes; Monocytes; Neutrophils; Sepsis

Indexed keywords

GENE PRODUCT; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECUM; CECUM LIGATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; FEMALE; IMMUNE RESPONSE; IMMUNE STATUS; INFECTION; INFLAMMATION; LIGATION; LYMPHOCYTE; MONOCYTE; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PUNCTURE; RISK ASSESSMENT; SEPSIS; SURVIVAL; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; SEPSIS; SURVIVAL ANALYSIS;

EID: 0042780320     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000080492.81509.29     Document Type: Article

References (43)

1. Oberholzer A, Oberholzer C, Moldawer LL: Sepsis syndromes: Understanding the role of innate and acquired immunity. Shock 2001; 16:83-96
2. Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999; 25:556-566
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
4. Reinhart K, Menges T, Gardlund B, et al: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29:765-769
5. Dinarello CA, Novick D, Puren AJ, et al: Overview of interleukin-18: More than an interferon-gamma inducing factor. J Leukoc Biol 1998; 63:658-664
6. Gracie JA, Forsey RJ, Chan WL, et al: A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104:1393-1401
7. Pizarro TT, Michie MH, Bentz M, et al: IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells. J Immunol 1999; 162:6829-6835
8. Grobmyer SR, Lin E, Lowry SF, et al: Elevation of IL-18 in human sepsis. J Clin Immunol 2000; 20:212-215
9. Endo S, Inada K, Yamada Y, et al: Interleukin 18 (IL-18) levels in patients with sepsis. J Med 2000; 31:15-20
10. Novick D, Kim SH, Fantuzzi G, et al: Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity 1999; 10:127-136
11. Remick DG, Bolgos GR, Siddiqui J, et al: Six at six: Interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002; 17:463-467
12. Remick DG, Newcomb DE, Bolgos GL, et al: Comparison of the mortality and inflammatory response of two models of sepsis: Lipopolysaccharide vs. cecal ligation and puncture. Shock 2000; 13:110-116
13. Remick DG, Call DR, Ebong SJ, et al: Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit Care Med 2001; 29:473-481
14. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock - A review of laboratory models and a proposal. J Surg Res 1980; 29:189-201
15. Ebong S, Call D, Nemzek J, et al: Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 1999; 67:6603-6610
16. Ebong SJ, Call DR, Bolgos G, et al: Immunopathologic responses to non-lethal sepsis. Shock 1999; 12:118-126
17. Nemzek JA, Siddiqui J, Remick DG: Development and optimization of cytokine ELISAs using commercial antibody pairs. J Immunol Methods 2001; 255:149-157
18. Faggioni R, Cattley RC, Guo J, et al: IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol 2001; 167:5913-5920
19. Calandra T, Gerain J, Heumann D, et al: High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 1991; 91:23-29
20. Damas P, Ledoux D, Nys M, et al: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215:356-362
21. Garcia VE, Uyemura K, Sieling PA, et al: IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. J Immunol 1999; 162:6114-6121
22. Qureshi MH, Zhang T, Koguchi Y, et al: Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with Cryptococcus neoformans. Eur J Immunol 1999; 29:643-649
23. Kawakami K, Qureshi MH, Zhang T, et al: Involvement of endogenously synthesized interleukin (IL)-18 in the protective effects of IL-12 against pulmonary infection with Cryptococcus neoformans in mice. FEMS Immunol Med Microbiol 2000; 27:191-200
24. Ohkusu K, Yoshimoto T, Takeda K, et al: Potentiality of interleukin-18 as a useful re-agent for treatment and prevention of Leishmania major infection. Infect Immun 2000; 68:2449-2456
25. Brieland JK, Jackson C, Hurst S, et al: Immunomodulatory role of endogenous interleukin-18 in gamma interferon-mediated resolution of replicative Legionella pneumophila lung infection. Infect Immun 2000; 68:6567-6573
26. Cai G, Kastelein R, Hunter CA: Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii. Infect Immun 2000; 68:6932-6938
27. Sugawara I, Yamada H, Kaneko H, et al: Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun 1999; 67:2585-2589
28. Yamada G, Shijubo N, Shigehara K, et al: Increased levels of circulating interleukin-18 in patients with advanced tuberculosis. Am J Respir Crit Care Med 2000; 161:1786-1789
29. Vankayalapati R, Wizel B, Weis SE, et al: Production of interleukin-18 in human tuberculosis. J Infect Dis 2000; 182:234-239
30. Netea MG, Fantuzzi G, Kullberg BJ, et al: Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J Immunol 2000; 164:2644-2649
31. Hochholzer P, Lipford GB, Wagner H, et al: Role of interleukin-18 (IL-18) during lethal shock: Decreased lipopolysaccharide sensitivity but normal superantigen reaction in IL-18-deficient mice. Infect Immun 2000; 68:3502-3508
32. O'Reilly M, Newcomb DE, Remick D: Endotoxin, sepsis, and the primrose path. Shock 1999; 12:411-420
33. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-1128
34. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25:1095-1100
35. Oberhoffer M, Vogelsang H, Russwurm S, et al: Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 1999; 37:363-368
36. Simpson AJ, Smith MD, Weverling GJ, et al: Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J Infect Dis 2000; 181:621-625
37. Terregino CA, Lopez BL, Karras DJ, et al: Endogenous mediators in emergency department patients with presumed sepsis: Are levels associated with progression to severe sepsis and death? Ann Emerg Med 2000; 35:26-34
38. McInnes IB, Gracie JA, Liew FY: Interleukin-18: A novel cytokine in inflammatory rheumatic disease. Arthritis Rheum 2001; 44:1481-1483
39. Kawashima M, Yamamura M, Taniai M, et al: Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001; 44:550-560
40. Siegmund B, Fantuzzi G, Rieder F, et al: Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1264-R1273
41. Monteleone G, Trapasso F, Parrello T, et al: Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999; 163:143-147
42. Warris A, Bjorneklett A, Gaustad P: Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344:1099-1100
43. Keane J, Gershon S, Wise RP, et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-1104